tiprankstipranks
Advertisement
Advertisement

Haleon Cancels 7.7 Million Shares in Ongoing Buyback Programme

Story Highlights
  • Haleon repurchased 7.74 million shares for cancellation under its buyback programme.
  • The buybacks reduce free-float, lifting ownership stakes and resetting voting-share totals.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Haleon Cancels 7.7 Million Shares in Ongoing Buyback Programme

Claim 30% Off TipRanks

An announcement from Haleon PLC ( (GB:HLN) ) is now available.

Haleon has continued executing its share buyback programme, purchasing 7,740,513 ordinary shares for cancellation between 7 and 10 April 2026 across multiple UK trading venues. Following these transactions, the company’s registered share capital stands at 8,919,824,040 ordinary shares, of which 12,439,998 are held in treasury, leaving 8,907,384,042 shares with voting rights.

The reduction in Haleon’s free-float through buybacks marginally increases existing shareholders’ proportional ownership and may support earnings per share over time. The updated voting share count also provides a new reference point for investors monitoring disclosure thresholds under UK transparency rules.

The most recent analyst rating on (GB:HLN) stock is a Buy with a £450.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.

Spark’s Take on HLN Stock

According to Spark, TipRanks’ AI Analyst, HLN is a Neutral.

The score is driven primarily by solid financial performance (consistent free cash flow and improving profitability) and a cautiously positive earnings outlook supported by margin gains and cost savings. This is tempered by weaker near-term technical momentum and only moderate valuation support.

To see Spark’s full report on HLN stock, click here.

More about Haleon PLC

Haleon plc is a consumer health company focused on improving everyday health through a portfolio spanning oral health, vitamins, minerals and supplements, pain relief, respiratory health, digestive health and therapeutic skin health. Its brands, including Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren, are used by over one billion consumers and widely recommended by health professionals worldwide.

Average Trading Volume: 20,048,631

Technical Sentiment Signal: Buy

Current Market Cap: £32.46B

See more insights into HLN stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1